8-K filed Jul 27, 2026 at 16:06 ET
Boston Scientific announced a new global restructuring program (2026 Restructuring Plan) approved by its Board on July 21, 2026, aimed at driving cost efficiencies and supporting strategic growth. The plan involves supply chain optimization, functional transformation, and headcount reductions, with estimated total pre-tax charges of $700M-$800M and expected annual pre-tax expense savings of ~$500M, though a substantial portion of savings will be reinvested. For a $65.8B market cap company, the charges are modest (~1.1% of market cap) and the plan is a proactive cost-efficiency move rather than a distress signal, but the lack of specific headcount numbers and multi-year timeline (through 2029) limits near-term impact.